KEY PAPERS


GUIDELINES


Royal College of Obstetricians and Gynaecologists (UK). Management of Beta Thalassaemia in Pregnancy Green-Top Guideline no. 66. 2014. [Link to guideline]


The Fred Hutchinson Cancer Research Center / Seattle Cancer Care Alliance -Long-term follow-up after hematopoietic stem cell transplant general guidelines for referring physicians (April 2013) [Link to guideline]

University Health Network - Toronto General Hospital. Guidelines for the care of patients in UHN Red Blood Cell Disorders Program. 2012. [Link to guideline]

Northern California Comprehensive Thalassemia Network and Children’s Hospital, Oakland. 2012 Thalassemia Standards of Care Guidelines. [Link to guideline]

Centres for Disease Control (CDC) - Diamond Blackfan Anemia Chelation Therapy Fact Sheet. [Link to factsheet]


Cooley’s Anemia Foundation. 2010 Position Statement on MRI-Based Hepatic Iron Assessment Methods. [Link to guideline]


ORIGINAL ARTICLES


Porter JB et al. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging sub study. Ann Hematol. 2013 Jan;92(2):211-9 [Link to abstract]

Nolte F et al. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol. 2013 Jan;92(2):191-8 [Link to abstract]


Taher A et al. Importance of optimal dosing ≥30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia. Eur J Haem. 2011; 87:355-65. [Link to abstract]


Pennyel DJ et al. Continued improvement in myocardial T2* over two years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Haematologica. 2011; 96(1):48-54. [Link to abstract]


House M et al. Relationship between brain R2(2) and liver and serum iron concentrations in elderly men. Mag Reson Med. 2010; 63:275-81. [Link to abstract]


Pathare A et al. Deferasirox (Exjade®) significantly improves cardiac T2* in heavily iron-overloaded patients with beta-thalassemia major. Ann Hematol 2010; 89(4):405-9. [Link to abstract]


Taher A et al. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients. Br J Haematol 2009;146(5):569-572. [Link to abstract]


Melis MA et al. A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. *Haematologica* 2008;93(10):1473-1479. [Link to full text]

Origa R et al. No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia. *Haematologica* 2008;93(10):1095-1096. [Link to full article]

Taher A et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. *Haematologica* 2008;93(10):1584-1586. [Link to full text article]


Olynkyj JK et al. Duration of hepatic iron exposure increases the risk of significant fibrosis in hereditary hemochromatosis: a new role for magnetic resonance imaging. *Am J Gastroenterol* 2005;100(4):837-841. [Link to abstract]


St Pierre TG et al. Single spin-echo proton transverse relaxometry of iron-loaded liver. *NMR Biomed* 2004;17(7):446-458. [Link to abstract]

Clark PR et al. Bi-exponential proton transverse relaxation rate (R2) image analysis using RF field intensity-weighted spin density projection: potential for R2 measurement of iron-loaded liver. *Magn Reson Imaging* 2003;21(5):519-530. [Link to abstract]

Clark PR et al. Proton transverse relaxation rate (R2) images of liver tissue; mapping local tissue iron concentrations with MRI. *Magn Reson Med*. 2003 Mar;49(3):572-5. [Link to abstract]

EDITORIALS


REVIEW ARTICLES


Alexiou, E. Methodologies and tools used today for measuring iron load. *Thalassemia Reports*, 2014. 4(3). [Link to full article]


Ware HM, Kwiatkowski JL: Optimal use of iron chelators in pediatric patients. Clinical Advances in Hematology & Oncology 2013, 11:433-441. [Link to full article]


Bird RJ et al. When should iron chelation therapy be considered in patients with myelodysplasia and other bone marrow failure syndromes with iron overload? Internal Medicine Journal. 2012; 42:450-5. [Link to abstract]


Cao A et al. Recent advances in β-thalassemias. Pediatric Reports. 2011; 3:e17. [Link to abstract]

Tziomalos K and Perifanis V. Liver iron content determination by magnetic resonance imaging. World J Gastro. 2010. 16(13): 1587-97. [Link to abstract]


Pavenski K et al. The real cost of iron chelation therapy. Transfusion 2007;47(10):1751-1752. [Link to Pubmed listing]


CONFERENCE PROCEEDINGS


Taher A et al. Deferasirox significantly reduces liver iron concentration in non-transfusion-dependent Thalassaemia patients with iron overload: results from the 1-year randomised, double-blind, placebo-controlled phase II THALASSA study. *ASH Annual Meeting*. 2011; Abstract 902.  


Vasavda N et al. Renal iron load in sickle cell disease correlates with hemolysis and transfusion history, but not with hepatic iron. *ASH Annual Meeting*. 2011; Abstract 5300.  

Inati A et al. Relationship between total iron removed by phlebotomy and iron removed from the liver in pediatric thalassemia major patients following curative stem cell transplant. *ASH Annual Meeting*. 2011; Abstract 4838.  

Gatterman N et al. Transfused myelodysplastic syndromes (MDS) patients have severe iron overload and relevant improvements in iron burden and liver function with deferasirox treatment: results from a pooled analysis. *ASH Annual Meeting*. 2011; Abstract 5019.  


Cheong J-W et al. Efficacy of ICT with Deferasirox in transfusional iron overload patients with MDS or AA. *ASH Annual Meeting Abstract*. 2009; Abstract 3810. [Link to abstract]  

Pennon D et al. Efficacy and safety of Deferasirox (Exjade®) in β-thalassemia patients with myocardial siderosis – 2 year results from the EPIC cardiac sub-study. *ASH Annual Meeting Abstract*. 2009; Abstract 4062. [Link to abstract]  

Taher A et al. Deferasirox (Exjade®) ≥ 30 mg/kg/day is effective in reducing iron burden in thalassemia major patients previously chelated with monotherapy or combination therapy. *ASH Annual Meeting Abstract*. 2009; Abstract 4058. [Link to abstract]  

Min Y et al. A multi-centre, open label study evaluating the efficacy of iron chelation therapy with deferasirox in transfusional iron overload patients with myelodysplastic syndromes or aplastic anemia using quantitative R2 MRI. *Leukaemia Research* 33: Supplement 1. 2009:S119-S120.  


Taher A et al. Deferasirox (Exjade®) treatment in pediatric β-thalassemia patients with high iron burden: 2.8 years results from ESCALATOR trial. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 3879. [Link to abstract]  

Taher A et al. Efficacy and safety of once-daily oral deferasirox (Exjade®) during a median of 2.7 years of treatment in heavily iron-overloaded patients with β-thalassemia. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 5409. [Link to abstract]  


Porter J et al. Effect of Deferasirox (Exjade®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective, 1-year EPIC trial. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 3881. [Link to abstract]  

Pennell D et al. Efficacy and safety of Deferasirox (Exjade®) in reducing cardiac iron in patients with β-thalassemia major: Results from the cardiac substudy of the EPIC trial. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 3873. [Link to abstract]  

Pennell D et al. Efficacy and safety of Deferasirox (Exjade®) in preventing cardiac iron in patients with normal baseline cardiac iron: Results from the cardiac substudy of the EPIC trial. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 3874. [Link to abstract]  

Gatterman N et al. Efficacy and safety of Deferasirox (Exjade®) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: Results from EPIC trial. *Blood (ASH Annual Meeting Abstracts)* 2008; 112: Abstract 633. [Link to abstract]  


Greenberg P et al. Change in liver iron concentration (LIC), serum ferritin (SF) and labile plasma iron (LPI) over 1 year of Deferasirox (DFX/Exjade®) therapy in a cohort of myelodysplastic patients. *Blood* (ASH Annual Meeting Abstracts) 2008; 112: Abstract 5083. [Link to abstract]

Piga A et al. Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with beta-thalassemia, treated with Deferasirox (ExJade(R), ICL670). *Blood* (ASH Annual Meeting Abstracts) 2005; 106: Abstract 2689. [Link to abstract]